SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based inNorway , announces that it has published its Annual Report for 2021. The Board of Directors has approved the 2021 annual financial statements prepared in accordance with the Norwegian Accounting Act and accounting standards and practises generally accepted inNorway . The financial statements are in accordance with the Q4 reporting published on16th February 2022 . "We look back on 2021 as the year of the formal validation of our technology in clinical trials and in the healthcare sector. This is the beginning of a breakthrough for the prevention and treatment of infections ", says CEOGeir Almås of SoftOx. "2021's successes far outweighed the challenges, and we are closer than ever to achieving our goals of sharing a new class of antimicrobials. The global attention on viruses and antimicrobial resistance confirms the need for what we have been working on for years - a new solution to fight infections." Attached to this notice are the Company's annual accounts for the financial year 2021, including the financial statements, annual report for the financial year 2021, and auditor's report. These documents are also available at the Company's website, https://soft-ox.com/press-releases-updates/. For further information, please contact: Geir Almås, CEO ofSoftOx Solutions AS , or Kristine Rød, CFO atSoftOx Solutions AS Mail: ir@soft-ox.com Phone: Front Desk: (+47) 948-59-599 AboutSoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian medtech/biotech company based inOslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com
Click here for more information
© Oslo Bors ASA, source